Abstract Details

Title Prevalence of Serious Adverse Pregnancy Outcomes After Exposure to Interferon Beta Before or During Pregnancy: Stratification by Characteristics of Pregnant Women with MS in a Register-based Cohort study in Finland and Sweden

Topic Multiple Sclerosis

Presentation(s) P11 - Poster Session 11 (8:00 AM-9:00 AM)

Poster/Presentation
Number 9-013

Objective To describe the prevalence of serious adverse pregnancy outcomes (SAPO) among pregnant women with multiple sclerosis (MS) exposed to only interferon-beta (IFNβ) and those unexposed to any MS disease modifying drugs (MSDMD), with stratification by maternal characteristics.

Background A recent cohort study in women with MS reported no increase in the prevalence of adverse pregnancy outcomes after exposure to IFNβ before or during pregnancy. However, differing prevalence by maternal characteristics is unknown.

Design/Methods This cohort study extracted register data from Finland (1996-2014) and Sweden (2005-2014) on pregnant women with MS 1) dispensed only IFNβ within 6 months before the last menstrual period (LMP) or during pregnancy (IFNβ-exposed, n=718 pregnancies) and 2) without dispensed MSDMD (unexposed, n=1397 pregnancies). The prevalence (%) of SAPO (consisting of elective terminations due to foetal anomaly, major congenital anomalies in live birth, and stillbirth) with 95% confidence intervals (CI) was analysed with stratification by maternal characteristics at LMP: time since MS diagnosis, duration of MS treatment, maternal age, and having chronic diseases.

Results The prevalence of SAPO appeared similar among the IFNβ-exposed vs. unexposed when MS was diagnosed ≤2 years (0.9%, 95%CI 0.1-3.2% vs. 3.0%, 1.6-5.2%) or 3-5 years (2.4%, 0.9-5.1% vs 6.0%, 4.0-8.6%) before LMP, and was comparable for >5 years (3.3%, 1.4-6.4% vs 3.0%, 1.7-4.8%). When stratified by duration of MS treatment, the prevalence among the IFNβ-exposed vs. unexposed with ≤2-year treatment was 1.3% (0.4-3.4%) vs 4.6% (2.9-6.9%), 3-5-year treatment 1.7% (0.5-4.4%) vs 4.9% (2.9-7.7%), and >5-year treatment 4.3% (1.9-8.3%) vs 2.7% (1.2-5.0%). The prevalence was similar among the IFNβ-exposed vs unexposed in strata by maternal age (≤20, 21-25, 26-30, 31-35, 36-40, >40 years) and having chronic diseases (yes/no).

Conclusions In this population-based observational study, the descriptive prevalence of SAPO appeared similar with IFNβ-exposure before or during pregnancy, when pregnant women with MS were stratified by maternal characteristics.

Authors/Disclosures
Jan A. Hillert, MD (Karolinska Institute, Neurology R54) PRESENTER	Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Celgene. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sandoz. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. The institution of Dr. Hillert has received research support from Biogen. The institution of Dr. Hillert has received research support from Celgene. The institution of Dr. Hillert has received research support from Merck. The institution of Dr. Hillert has received research support from Novartis. The institution of Dr. Hillert has received research support from Sanofi. The institution of Dr. Hillert has received research support from Roche.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Yvonne Geissbuhler (Novartis Pharma AG)	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Auli Verkkoniemi-Ahola (Jorvi Hospital)	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file

�鶹��ýӳ��

�鶹��ýӳ��

Abstract Details